Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy

Next Previous
Trial Profile

Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 30 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Dec 2025.
  • 29 Sep 2023 Number of treatment arms have been increased from 1 to 2 by the addition of Experimental: Monogenetic Epileptic Encephalopathy arm comprising 30 more children. Inclusion criteria is updated to decrease the minimum age limit from 2 months to 0 months. Timelines for all the primary end-points have been modified.
  • 29 Sep 2023 Planned number of patients changed from 20 to 50.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top